Insider Trading Alert - BCR, ADS And PII Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 27, 2014, 119 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $99.26 to $40,800,000.00.

Highlighted Stocks Traded by Insiders:

C.R. Bard (BCR) - FREE Research Report

Kelly Bronwen K who is VP - Human Resources at C.R. Bard sold 2,917 shares at $141.99 on Feb. 27, 2014. Following this transaction, the VP - Human Resources owned 21,847 shares meaning that the stake was reduced by 11.78% with the 2,917-share transaction.

The shares most recently traded at $145.06, up $3.07, or 2.12% since the insider transaction. Historical insider transactions for C.R. Bard go as follows:

  • 4-Week # shares sold: 38,526
  • 12-Week # shares sold: 70,385
  • 24-Week # shares sold: 81,682

The average volume for C.R. Bard has been 652,500 shares per day over the past 30 days. C.R. Bard has a market cap of $11.1 billion and is part of the health care sector and health services industry. Shares are up 8.03% year-to-date as of the close of trading on Thursday.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The stock currently has a dividend yield of 0.59%. The company has a P/E ratio of 17.1. Currently there are 4 analysts that rate C.R. Bard a buy, 1 analyst rates it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BCR - FREE

TheStreet Quant Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full C.R. Bard Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts